NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free ARWR Stock Alerts $23.92 +1.59 (+7.12%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$22.24▼$24.3050-Day Range$22.33▼$36.0852-Week Range$20.67▼$42.48Volume1.08 million shsAverage Volume778,002 shsMarket Capitalization$2.96 billionP/E RatioN/ADividend YieldN/APrice Target$53.45 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Arrowhead Pharmaceuticals alerts: Email Address Arrowhead Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside123.5% Upside$53.45 Price TargetShort InterestBearish7.16% of Shares Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.19Based on 4 Articles This WeekInsider TradingSelling Shares$3.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.70) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.70 out of 5 starsMedical Sector224th out of 910 stocksPharmaceutical Preparations Industry88th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageArrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.16% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently decreased by 3.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.55. Previous Next 1.2 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arrowhead Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold 5,842.34% more of their company's stock than they have bought. Specifically, they have bought $54,990.00 in company stock and sold $3,267,693.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -8.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -8.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 8.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Read More ARWR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARWR Stock News HeadlinesApril 21, 2024 | ca.finance.yahoo.comArrowhead Pharmaceuticals, Inc. (ARWR)April 16, 2024 | finance.yahoo.comInstitutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year lossesApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial ResultsApril 7, 2024 | businesswire.comArrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & ExpoApril 5, 2024 | investorplace.comThe 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024March 30, 2024 | seekingalpha.comArrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)March 25, 2024 | finance.yahoo.comArrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical DataApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 16, 2024 | finance.yahoo.comARWR Apr 2024 20.000 putMarch 16, 2024 | nasdaq.comNoteworthy Thursday Option Activity: ARWR, RBLX, MRNAMarch 16, 2024 | finance.yahoo.comARWR Apr 2024 25.000 callMarch 15, 2024 | stocknews.comBiotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?March 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR)March 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 12, 2024 | morningstar.comArrowhead Pharmaceuticals Inc ARWRMarch 11, 2024 | investorplace.comThe 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024March 9, 2024 | finance.yahoo.comArrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 SharesMarch 8, 2024 | markets.businessinsider.comArrowhead Pharmaceutical Gains Over Initiation Of Phase 1/2a Study Of ARO-DM1March 8, 2024 | businesswire.comArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic DystrophyFebruary 28, 2024 | msn.comArrowhead Pharmaceuticals jumps amid takeover speculationFebruary 25, 2024 | investorplace.com7 Oversold Russell 2000 Stocks to Add to Your February Buy ListFebruary 17, 2024 | ca.finance.yahoo.comARWR Mar 2024 30.000 callFebruary 12, 2024 | nasdaq.comArrowhead Pharmaceuticals, Inc. Common Stock (ARWR)February 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arrowhead Pharmaceuticals with Strong Growth Projections and Pipeline PotentialFebruary 8, 2024 | markets.businessinsider.comStrategic Developments and Financial Strength Underpin Buy Rating for Arrowhead PharmaceuticalsFebruary 8, 2024 | finance.yahoo.comARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal YearSee More Headlines Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/06/2024Today4/23/2024Next Earnings (Estimated)5/07/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees525Year FoundedN/APrice Target and Rating Average Stock Price Target$53.45 High Stock Price Target$90.00 Low Stock Price Target$34.00 Potential Upside/Downside+123.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,270,000.00 Net Margins-163.32% Pretax Margin-166.93% Return on Equity-90.77% Return on Assets-38.56% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual Sales$240.74 million Price / Sales12.31 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book8.93Miscellaneous Outstanding Shares123,900,000Free Float118,322,000Market Cap$2.96 billion OptionableOptionable Beta0.71 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Christopher R. Anzalone Ph.D. (Age 55)CEO, President & Director Comp: $1.6MMr. Kenneth A. Myszkowski (Age 58)Chief Financial Officer Comp: $834.34kMr. Patrick O'Brien J.D. (Age 60)PharmD, COO, General Counsel & Secretary Comp: $835.14kDr. James C. Hamilton M.D. (Age 46)MBA, Chief of Discovery & Translational Medicine Comp: $762.14kDr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoDr. Vincent Anzalone CFAHead of Investor Relations & VPMr. Howard LovyDirector of CommunicationsDr. Bruce D. Given M.D. (Age 70)Chief Medical Scientist Comp: $486.31kDr. Mark Seefeld (Age 70)Head of Toxicology & VP Ms. Tracie Oliver (Age 62)Chief Commercial Officer Comp: $449.58kMore ExecutivesKey CompetitorsHUTCHMEDNASDAQ:HCMACADIA PharmaceuticalsNASDAQ:ACADIDEAYA BiosciencesNASDAQ:IDYAMoonLake ImmunotherapeuticsNASDAQ:MLTXAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInsiders & InstitutionsWealth Effects LLCBought 2,610 shares on 4/23/2024Ownership: 0.133%State of Alaska Department of RevenueBought 1,860 shares on 4/19/2024Ownership: 0.011%State of Michigan Retirement SystemBought 4,800 shares on 4/18/2024Ownership: 0.025%Myecfo LLCBought 18,497 shares on 4/18/2024Ownership: 0.015%Hennion & Walsh Asset Management Inc.Bought 4,523 shares on 4/17/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions ARWR Stock Analysis - Frequently Asked Questions Should I buy or sell Arrowhead Pharmaceuticals stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares. View ARWR analyst ratings or view top-rated stocks. What is Arrowhead Pharmaceuticals' stock price target for 2024? 12 equities research analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' stock. Their ARWR share price targets range from $34.00 to $90.00. On average, they anticipate the company's share price to reach $53.45 in the next year. This suggests a possible upside of 123.5% from the stock's current price. View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts. How have ARWR shares performed in 2024? Arrowhead Pharmaceuticals' stock was trading at $30.60 on January 1st, 2024. Since then, ARWR stock has decreased by 21.8% and is now trading at $23.92. View the best growth stocks for 2024 here. When is Arrowhead Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ARWR earnings forecast. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its earnings results on Tuesday, February, 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.46. The biotechnology company had revenue of $3.55 million for the quarter, compared to analysts' expectations of $35.60 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 90.77% and a negative net margin of 163.32%. Arrowhead Pharmaceuticals's revenue was down 94.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.39) EPS. What ETFs hold Arrowhead Pharmaceuticals' stock? ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), FMC Excelsior Focus Equity ETF (FMCX) and Principal Healthcare Innovators ETF (BTEC).Syntax Stratified MidCap ETF (SMDY). What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD). Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wealth Effects LLC (0.13%), Hennion & Walsh Asset Management Inc. (0.04%), Global Assets Advisory LLC (0.03%), State of Michigan Retirement System (0.02%), Myecfo LLC (0.01%) and State of Alaska Department of Revenue (0.01%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, Hongbo Lu, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARWR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
